OPL 0401
Alternative Names: OPL-0401Latest Information Update: 06 Mar 2024
At a glance
- Originator Courier Therapeutics
- Developer Valo Health
- Class Small molecules
- Mechanism of Action Rho-associated kinase inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic retinopathy
- Phase I Diabetic complications
Most Recent Events
- 05 Mar 2024 Valo Health completes enrolment in phase-II Spectra clinical trials in Diabetic retinopathy in USA (PO, Capsule) (NCT05393284)
- 25 Jul 2022 Phase-II clinical trials in Diabetic retinopathy in USA (PO, Capsule) (NCT05393284)
- 31 May 2022 Valo Health plans a phase II trial in diabetic retinopathy (In adults, In the elderly) in USA (NCT05393284)